Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer

Arnaldo A. Arbini, Margherita Greco, Jorge L. Yao, Patricia Bourne, Ersilia Marra, Jer Tsong Hsieh, Paul A. Di Sant'Agnese, Loredana Moro

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

BRCA2 (breast cancer 2, early onset) is a tumor suppressor gene that confers increased susceptibility for prostate cancer (PCa). Previous in vitro experiments demonstrated that Skp2, an E3 ubiquitin ligase aberrantly overexpressed in PCa, is involved in the proteolytic degradation of BRCA2 in PCa cells, suggesting that the BRCA2-Skp2 interaction may play a role in prostate tumorigenesis. Herein, we investigated BRCA2 and Skp2 expression during PCa development using a prostate TMA. Although luminal and basal benign prostate epithelium exhibited moderate to strong nuclear BRCA2 immunostaining, the intensity and number of positive nuclei decreased significantly in high-grade prostatic intraepithelial neoplasia and PCa. Decreased frequency and intensity of nuclear BRCA2 labeling were inversely correlated with Skp2 expression in high-grade prostatic intraepithelial neoplasia and PCa. To functionally assess the effects of BRCA2 and Skp2 expression on prostate malignant transformation, we overexpressed Skp2 in normal immortalized prostate cells. Skp2 overexpression reduced BRCA2 protein and promoted cell growth and migration. A similar phenotype was observed after reduction of BRCA2 protein levels using specific BRCA2 small-interfering RNA. Forced BRCA2 expression in Skp2-overexpressing stable transfectants inhibited the migratory and growth properties by >60%. These results show that loss of BRCA2 expression during prostate tumor development is strongly correlated with both migratory behavior and cancer growth and include Skp2 as a BRCA2 proteolytic partner in vivo.

Original languageEnglish (US)
Pages (from-to)2367-2376
Number of pages10
JournalAmerican Journal of Pathology
Volume178
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Prostate
Prostatic Neoplasms
BRCA2 Protein
Prostatic Intraepithelial Neoplasia
Growth
Ubiquitin-Protein Ligases
Tumor Suppressor Genes
Small Interfering RNA
Cell Movement
human BRCA2 protein
Neoplasms
Carcinogenesis
Epithelium
Breast Neoplasms
Phenotype

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer. / Arbini, Arnaldo A.; Greco, Margherita; Yao, Jorge L.; Bourne, Patricia; Marra, Ersilia; Hsieh, Jer Tsong; Di Sant'Agnese, Paul A.; Moro, Loredana.

In: American Journal of Pathology, Vol. 178, No. 5, 05.2011, p. 2367-2376.

Research output: Contribution to journalArticle

Arbini, AA, Greco, M, Yao, JL, Bourne, P, Marra, E, Hsieh, JT, Di Sant'Agnese, PA & Moro, L 2011, 'Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer', American Journal of Pathology, vol. 178, no. 5, pp. 2367-2376. https://doi.org/10.1016/j.ajpath.2011.01.050
Arbini, Arnaldo A. ; Greco, Margherita ; Yao, Jorge L. ; Bourne, Patricia ; Marra, Ersilia ; Hsieh, Jer Tsong ; Di Sant'Agnese, Paul A. ; Moro, Loredana. / Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer. In: American Journal of Pathology. 2011 ; Vol. 178, No. 5. pp. 2367-2376.
@article{64f35066d3d245368f05b5d592a980eb,
title = "Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer",
abstract = "BRCA2 (breast cancer 2, early onset) is a tumor suppressor gene that confers increased susceptibility for prostate cancer (PCa). Previous in vitro experiments demonstrated that Skp2, an E3 ubiquitin ligase aberrantly overexpressed in PCa, is involved in the proteolytic degradation of BRCA2 in PCa cells, suggesting that the BRCA2-Skp2 interaction may play a role in prostate tumorigenesis. Herein, we investigated BRCA2 and Skp2 expression during PCa development using a prostate TMA. Although luminal and basal benign prostate epithelium exhibited moderate to strong nuclear BRCA2 immunostaining, the intensity and number of positive nuclei decreased significantly in high-grade prostatic intraepithelial neoplasia and PCa. Decreased frequency and intensity of nuclear BRCA2 labeling were inversely correlated with Skp2 expression in high-grade prostatic intraepithelial neoplasia and PCa. To functionally assess the effects of BRCA2 and Skp2 expression on prostate malignant transformation, we overexpressed Skp2 in normal immortalized prostate cells. Skp2 overexpression reduced BRCA2 protein and promoted cell growth and migration. A similar phenotype was observed after reduction of BRCA2 protein levels using specific BRCA2 small-interfering RNA. Forced BRCA2 expression in Skp2-overexpressing stable transfectants inhibited the migratory and growth properties by >60{\%}. These results show that loss of BRCA2 expression during prostate tumor development is strongly correlated with both migratory behavior and cancer growth and include Skp2 as a BRCA2 proteolytic partner in vivo.",
author = "Arbini, {Arnaldo A.} and Margherita Greco and Yao, {Jorge L.} and Patricia Bourne and Ersilia Marra and Hsieh, {Jer Tsong} and {Di Sant'Agnese}, {Paul A.} and Loredana Moro",
year = "2011",
month = "5",
doi = "10.1016/j.ajpath.2011.01.050",
language = "English (US)",
volume = "178",
pages = "2367--2376",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Skp2 overexpression is associated with loss of BRCA2 protein in human prostate cancer

AU - Arbini, Arnaldo A.

AU - Greco, Margherita

AU - Yao, Jorge L.

AU - Bourne, Patricia

AU - Marra, Ersilia

AU - Hsieh, Jer Tsong

AU - Di Sant'Agnese, Paul A.

AU - Moro, Loredana

PY - 2011/5

Y1 - 2011/5

N2 - BRCA2 (breast cancer 2, early onset) is a tumor suppressor gene that confers increased susceptibility for prostate cancer (PCa). Previous in vitro experiments demonstrated that Skp2, an E3 ubiquitin ligase aberrantly overexpressed in PCa, is involved in the proteolytic degradation of BRCA2 in PCa cells, suggesting that the BRCA2-Skp2 interaction may play a role in prostate tumorigenesis. Herein, we investigated BRCA2 and Skp2 expression during PCa development using a prostate TMA. Although luminal and basal benign prostate epithelium exhibited moderate to strong nuclear BRCA2 immunostaining, the intensity and number of positive nuclei decreased significantly in high-grade prostatic intraepithelial neoplasia and PCa. Decreased frequency and intensity of nuclear BRCA2 labeling were inversely correlated with Skp2 expression in high-grade prostatic intraepithelial neoplasia and PCa. To functionally assess the effects of BRCA2 and Skp2 expression on prostate malignant transformation, we overexpressed Skp2 in normal immortalized prostate cells. Skp2 overexpression reduced BRCA2 protein and promoted cell growth and migration. A similar phenotype was observed after reduction of BRCA2 protein levels using specific BRCA2 small-interfering RNA. Forced BRCA2 expression in Skp2-overexpressing stable transfectants inhibited the migratory and growth properties by >60%. These results show that loss of BRCA2 expression during prostate tumor development is strongly correlated with both migratory behavior and cancer growth and include Skp2 as a BRCA2 proteolytic partner in vivo.

AB - BRCA2 (breast cancer 2, early onset) is a tumor suppressor gene that confers increased susceptibility for prostate cancer (PCa). Previous in vitro experiments demonstrated that Skp2, an E3 ubiquitin ligase aberrantly overexpressed in PCa, is involved in the proteolytic degradation of BRCA2 in PCa cells, suggesting that the BRCA2-Skp2 interaction may play a role in prostate tumorigenesis. Herein, we investigated BRCA2 and Skp2 expression during PCa development using a prostate TMA. Although luminal and basal benign prostate epithelium exhibited moderate to strong nuclear BRCA2 immunostaining, the intensity and number of positive nuclei decreased significantly in high-grade prostatic intraepithelial neoplasia and PCa. Decreased frequency and intensity of nuclear BRCA2 labeling were inversely correlated with Skp2 expression in high-grade prostatic intraepithelial neoplasia and PCa. To functionally assess the effects of BRCA2 and Skp2 expression on prostate malignant transformation, we overexpressed Skp2 in normal immortalized prostate cells. Skp2 overexpression reduced BRCA2 protein and promoted cell growth and migration. A similar phenotype was observed after reduction of BRCA2 protein levels using specific BRCA2 small-interfering RNA. Forced BRCA2 expression in Skp2-overexpressing stable transfectants inhibited the migratory and growth properties by >60%. These results show that loss of BRCA2 expression during prostate tumor development is strongly correlated with both migratory behavior and cancer growth and include Skp2 as a BRCA2 proteolytic partner in vivo.

UR - http://www.scopus.com/inward/record.url?scp=79959245402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959245402&partnerID=8YFLogxK

U2 - 10.1016/j.ajpath.2011.01.050

DO - 10.1016/j.ajpath.2011.01.050

M3 - Article

VL - 178

SP - 2367

EP - 2376

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 5

ER -